secwatch.observer — SEC 8-K summary
======================================

Issuer:     Personalis, Inc. (PSNL)
CIK:        0001527753
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001193125-25-273416
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Personalis receives Medicare coverage for NeXT Personal in breast cancer MRD surveillance
--------------------------------------------------------------------------------

- CMS covers NeXT Personal Dx Breast MRD test for post-treatment surveillance of stage II/III breast cancer recurrence.
- Reimbursement rate $3,878 for NeXT Personal Dx Breast MRD test; $1,158 for NeXT Personal Single Plasma Test.
- Coverage effective retroactively from October 7, 2025; Single Plasma test available up to 6 years post-treatment.
- Dx Breast MRD test covered once per cancer diagnosis; expands market access for Personalis.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525273416/0001193125-25-273416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527753/000119312525273416/d158834d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-273416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer